| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
EVP R&D, Chief Medical Officer | SVP, Med Dev/ Med Affairs, CMO
1 company
Hopkinson Craig C. is an EVP R&D, Chief Medical Officer at Alkermes plc.. Recent SEC Form 4 filings include 0 buys and 10 sells.
Estimated insider holdings value: $3.5M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 30, 2025 | ALKS Alkermes Plc. | EVP R&D, Chief Medical Officer | Sale+OE | 100,918 | $32.05 | $3,234,381.53 | -69.5% | -9.8% | +6.2% | |
| Dec 9, 2024 | ALKS Alkermes Plc. | EVP R&D, Chief Medical Officer | Sale+OE | 61,151 | $32.07 | $1,961,406.09 | -56.2% | +12.6% | -9.2% | |
| Dec 5, 2024 | ALKS Alkermes Plc. | EVP R&D, Chief Medical Officer | Sell | 9,221 | $31.50 | $290,461.50 | -13.4% | +13.1% | -5.4% | |
| Dec 4, 2024 | ALKS Alkermes Plc. | EVP R&D, Chief Medical Officer | Sell | 14,349 | $30.77 | $441,550.30 | -17.2% | +14.0% | -5.7% | |
| Nov 11, 2024 | ALKS Alkermes Plc. | EVP R&D, Chief Medical Officer | Sale+OE | 58,996 | $30.08 | $1,774,576.08 | -41.5% | +3.8% | +12.4% | |
| Nov 6, 2024 | ALKS Alkermes Plc. | EVP R&D, Chief Medical Officer | Sell | 10,471 | $29.53 | $309,168.84 | -9.5% | +6.9% | +8.2% | |
| Feb 23, 2022 | ALKS Alkermes Plc. | EVP R&D, Chief Medical Officer | Sell | 11,983 | $24.76 | $296,649.95 | -40.0% | +17.5% | +13.4% | |
| Feb 18, 2022 | ALKS Alkermes Plc. | EVP R&D, Chief Medical Officer | Sale+OE | 2,306 | $25.17 | $58,042.02 | -19.5% | +17.5% | +11.9% | |
| Jun 9, 2021 | ALKS Alkermes Plc. | EVP R&D, Chief Medical Officer | Sell | 882 | $24.60 | $21,697.20 | -100% | +20.1% | +13.9% | |
| Apr 15, 2021 | ALKS Alkermes Plc. | EVP R&D, Chief Medical Officer | Sell | 28,920 | $19.72 | $570,287.94 | -100% | +21.2% | +48.5% |